Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRNP | P04156 | 1/20 | 0.34 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.32 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.31 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30184539 | 1.00 | PRNP (0.34) | PRNPPSMB8GABRA1GABRB2ALDH1A1 | |
| SCHEMBL31107739 | 0.79 | — | — | |
| SCHEMBL30640501 | 0.70 | NPC1 (0.45) | ALDH1A1MEN1KMT2A | |
| SCHEMBL8038388 | 0.70 | PSMB8 (0.33) | PSMB8GABRA1GABRB2ALDH1A1 | |
| SCHEMBL11933059 | 0.70 | PSMB8 (0.43) | PRNPPSMB8ALDH1A1 | |
| SCHEMBL31107782 | 0.69 | PIM1 (0.32) | PSMB8ALDH1A1MEN1KMT2A | |
| SCHEMBL27002569 | 0.69 | DYRK1A (0.37) | PSMB8ALDH1A1MEN1KMT2A | |
| SCHEMBL17207338 | 0.68 | AHR (0.36) | PSMB8 | |
| SCHEMBL10432656 | 0.68 | PSMB8 (0.36) | PSMB8GABRA1GABRB2ALDH1A1 | |
| SCHEMBL1293277 | 0.68 | GABRA1 (0.48) | PRNPGABRA1GABRB2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240400591-A1 | COMPOUNDS TARGETING MUTANT OF P53 | JACOBIO PHARMACEUTICALS CO., LTD. (CN) | 2024-12-05 | — | — | US | disclosed |
| CN-117986235-A | P53-Y220C selective small molecule reactivation agent compound, pharmaceutical composition and application thereof | 长春金赛药业有限责任公司 | 2024-05-07 | — | — | CN | disclosed |
| CN-117813295-A | Compounds targeting p53 mutants | 北京加科思新药研发有限公司 | 2024-04-02 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240400591-A1 | COMPOUNDS TARGETING MUTANT OF P53 | TP53, TP53BP1, MDM2 | PRNP 1337/4885PSMB8 1717/4885GABRA1 4552/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.